Nitto Denko Avecia Inc. 125 Fortune Boulevard
Post# of 22456
Posted On: 01/19/2016 10:13:31 PM
Nitto Denko Avecia Inc.
125 Fortune Boulevard
Milford Massachusetts 01757 U.S.A.
Phone: 508-532-2500 Fax: 508-532-2503
Avecia, a recognized leader in the development and manufacture of DNA and RNA therapeutics, offers customized solutions and proven expertise that can seamlessly support your oligonucleotide or small molecule product from small scale modeling to commercial launch. As a part of the Nitto Denko Corporation, Avecia’s commitment to the future is driven by innovative ideas and flexible solutions, designed to provide our customers with the best in service, quality, and technology.
At Avecia’s two FDA-inspected cGMP facilities, we can produce pre-clinical, clinical, and commercial oligonucleotide products; our manufacturing team produces an extensive variety of API, including antisense, siRNA, aptamers, immunostimulants, miRNA, and molecular decoys. We manufacture to meet the international requirements of ICH Q7, and maintain an outstanding compliance record through customer and FDA audits. We also utilize the guidance of ICH Q8, 9, 10, and 11. Our aim is to leverage our wealth of experience, and knowledge of the regulatory requirements of each market segment, to ensure we exceed our customer’s expectations.
In addition to our oligonucleotide services, Avecia now provides small molecule development and manufacturing, with a broad range of synthesis and related services for the development of small molecules, including di- and tri-nucleotides. Our fully equipped process development labs, kilo labs and pilot plant provide a comprehensive path, from grams to tens of kilograms, in one facility, with a focus on high quality, flexibility, and speed.
Avecia’s analytical and process development teams have extensive experience, ranging from pre-clinical to clinical compounds and commercial products. We have successfully completed numerous process validations, and have performed technical transfers of compounds at all phases into our facility. Our mission is to build value for our customers as they progress along the drug development journey.
Whether you are in preclinical stages, or ready for a commercial launch, you can be assured of the best in both technology and service when you turn to the world-leading capabilities of Nitto Denko Avecia.
http://www.biospace.com/company_profile.aspx?...yId=981120
Aminoacyl β-naphthylamides as substrates and modulators of AcrB multidrug efflux pump
1Present address: Life Science Research Center, Nitto Denko Corp., Ibaraki, Osaka 567-8680, Japan.
http://www.pnas.org/content/early/2016/01/15/...3.abstract
125 Fortune Boulevard
Milford Massachusetts 01757 U.S.A.
Phone: 508-532-2500 Fax: 508-532-2503
Avecia, a recognized leader in the development and manufacture of DNA and RNA therapeutics, offers customized solutions and proven expertise that can seamlessly support your oligonucleotide or small molecule product from small scale modeling to commercial launch. As a part of the Nitto Denko Corporation, Avecia’s commitment to the future is driven by innovative ideas and flexible solutions, designed to provide our customers with the best in service, quality, and technology.
At Avecia’s two FDA-inspected cGMP facilities, we can produce pre-clinical, clinical, and commercial oligonucleotide products; our manufacturing team produces an extensive variety of API, including antisense, siRNA, aptamers, immunostimulants, miRNA, and molecular decoys. We manufacture to meet the international requirements of ICH Q7, and maintain an outstanding compliance record through customer and FDA audits. We also utilize the guidance of ICH Q8, 9, 10, and 11. Our aim is to leverage our wealth of experience, and knowledge of the regulatory requirements of each market segment, to ensure we exceed our customer’s expectations.
In addition to our oligonucleotide services, Avecia now provides small molecule development and manufacturing, with a broad range of synthesis and related services for the development of small molecules, including di- and tri-nucleotides. Our fully equipped process development labs, kilo labs and pilot plant provide a comprehensive path, from grams to tens of kilograms, in one facility, with a focus on high quality, flexibility, and speed.
Avecia’s analytical and process development teams have extensive experience, ranging from pre-clinical to clinical compounds and commercial products. We have successfully completed numerous process validations, and have performed technical transfers of compounds at all phases into our facility. Our mission is to build value for our customers as they progress along the drug development journey.
Whether you are in preclinical stages, or ready for a commercial launch, you can be assured of the best in both technology and service when you turn to the world-leading capabilities of Nitto Denko Avecia.
http://www.biospace.com/company_profile.aspx?...yId=981120
Aminoacyl β-naphthylamides as substrates and modulators of AcrB multidrug efflux pump
1Present address: Life Science Research Center, Nitto Denko Corp., Ibaraki, Osaka 567-8680, Japan.
http://www.pnas.org/content/early/2016/01/15/...3.abstract
(0)
(0)Quantum Materials Corp. (QTMM) Stock Research Links
Scroll down for more posts ▼